Dr. Reddy’s Laboratories has launched Methylprednisolone Sodium Succinate for Injection, USP, the generic equivalent of SOLU-MEDROL (methylprednisolone sodium succinate for injection, USP) in the U.S. Market approved by the U.S. Food and Drug Administration (USFDA).
The SOLU-MEDROL brand and generic had U.S. sales of around $144 million MAT for the most recent twelve months ending in February 2022 according to IQVIA Health.
Dr. Reddy’s Methylprednisolone Sodium Succinate for Injection, USP, is supplied in 40 mg/vial, 125 mg/vial single-dose vials each carton containing 25 vials; 500 mg and 1 gm multi-dose vial each carton containing 1 vial.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
